Related Experiment Video
Updated: Jul 5, 2026
06:10
Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye
Published on: March 30, 2020
8.5K
Ciliary Neurotrophic Factor Therapy for Macular Telangiectasia Type 2: A Systematic Review
Aswen Sriranganathan1, Zwetlana Rajesh2, Andrew Mihalache2
1Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Retina (Philadelphia, Pa.)
|April 9, 2026
Summary
Ciliary neurotrophic factor (CNTF) therapy shows promise in slowing retinal degeneration for macular telangiectasia (MacTel) patients. Further trials are needed to confirm long-term efficacy and functional preservation.
Area of Science:
- Ophthalmology
- Retinal Diseases
- Neuroscience
Background:
- Macular telangiectasia (MacTel) is a degenerative retinal disease affecting central vision.
- Current treatments for MacTel have limited efficacy in halting disease progression.
- Ciliary neurotrophic factor (CNTF) is a neurotrophic factor with potential therapeutic applications for retinal degeneration.
Purpose of the Study:
- To systematically review the structural and functional outcomes of ciliary neurotrophic factor (CNTF) treatment in patients with type 2 macular telangiectasia (MacTel).
Main Methods:
- A systematic review of studies from Medline, Embase, and Cochrane Library databases (inception to May 2024).
- Primary outcome: best-corrected visual acuity (BCVA). Secondary outcome: ellipsoid zone (EZ) discontinuity area.
- Risk of bias assessed using ROBINS-1 and Cochrane ROB2 tools.
Main Results:
- Five studies (498 eyes, 422 patients) were included.
- CNTF treatment demonstrated decreased progression of retinal degeneration and reduced decline in reading speed compared to sham.
- Smaller changes in EZ defect areas and slowed structural progression were observed; functional outcomes were variable, with some safety concerns like miosis.
Conclusions:
- CNTF therapy appears to slow retinal degeneration and preserve visual function in MacTel patients.
- CNTF shows promise for earlier stages of MacTel.
- Further trials are required to fully assess long-term efficacy and safety.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:27Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...